TARGET applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. Investigators form a collaborative network to facilitate discovery of molecular targets and translate those findings into the clinic. TARGET is managed by NCI’s Office of Cancer Genomics and Cancer Therapy Evaluation Program.
Therapeutically Applicable Research to Generate Effective Treatments
TARGET: Therapeutically Applicable Research to Generate Effective Treatments
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells, the cells in the body that normally fight infection.
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a cancer that originates in the bone marrow from immature white blood cells known as myeloblasts. About 25% of all children with leukemia have AML.
Pediatric kidney tumors fall into four primary categories: Wilms tumors (~85% of all cases), clear cell sarcomas of the kidney (~5%), congenital mesoblastic nephromas (~4%), and rhabdoid tumors of the kidney (~3%). The TARGET initiative is investigating three of these tumor types.
Neuroblastoma (NBL) is a cancer that arises in immature nerve cells of the sympathetic nervous system, primarily affecting infants and children.
Osteosarcoma (OS) is the most common type of bone cancer in children and adolescents.